Sustainability | September 17, 2024
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
